ESTABLISHMENT LABS H (ESTA) is drawing unusual attention today. Our newswire has captured 5 stories on ESTA across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
Establishment Labs Holdings stock rose 7.96% to $62.49 on Tuesday, driven by a new Buy rating from Stifel and a reiterated Buy from TD Cowen ahead of a key FDA decision. The shares also printed 12 fresh 52-week highs during the session, reflecting strong momentum despite a modest volume print.
Stifel initiated coverage of Establishment Labs with a Buy rating and a price target of $85. Separately, TD Cowen reiterated its Buy rating on the stock, maintaining a price target of $117 ahead of an upcoming FDA decision. The company also filed an 8-K with the SEC on October 15, 2026, disclosing the entry into a material definitive agreement. This filing included financial statements and exhibits. In related news, Establishment Labs extended its master supply agreement with NuSil Technology to December 31, 2031. The company also announced that the FDA approved 28 new sizes of Motiva breast implants, which are available before year-end. Additionally, Establishment Labs is scheduled to present new breast tissue preservation data and announce minimally invasive product extensions at the 11th World Symposium on Ergonomic Implants.
The stock opened at $57.25, a 1.1% gap down from the prior close of $57.88. The session low was $57.25 at 7:25 AM ET, while the session high reached $62.77 at 10:55 AM ET. Volume stood at 0.1 million shares, which is 0.2 times the three-month daily average. The company has a market capitalization of $1.7 billion and is currently unprofitable, with a trailing twelve-month EPS of $1.29. Revenue grew 38.6% over the trailing twelve months, though the net margin stands at 15.8%. The stock has a beta of 1.06 and a 52-week range of $40.59 to $97.59. The 30-day average sentiment score is 64 out of 100, while the last seven days average is 60 out of 100, indicating a slight deterioration in recent sentiment.
Investors will monitor the upcoming FDA decision, which is a primary driver for the current analyst ratings. The company’s presentation at the 11th World Symposium on Ergonomic Implants will also provide further details on its product extensions and data.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Establishment Labs (ESTA) stock jumps as Stifel starts coverage with Buy and $84 target, citing a stronger-than-expected breast augmentation market. Read more here.
Establishment Labs stock rating reiterated at Buy by TD Cowen ahead of FDA decision
Filed: 2026-10-15 AccNo: 0001104659-26-115928 Size: 225 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stifel initiates Establishment Labs stock with buy rating, $85 target
ESTABLISHMENT LABS H (ESTA) is drawing unusual attention today. Our newswire has captured 5 stories on ESTA across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100). The most recent driver: "Establishment Labs a new Buy at Stifel on end-market prospects" (Seeking Alpha).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of ESTA coverage reads 61/100 over 5 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on ESTA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ESTA move explainers: 2026-10-15